Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Noninvasive MRA-derived fractional flow for intracranial stenosis: methodological evaluation and hemodynamic insights.

Frontiers in neurology·2026
Same author

Current Status of Diagnosis, Treatment, and Prevention of Helicobacter pylori Infection in China: A 2024-2025 National Multicenter Cross-Sectional Study.

Helicobacter·2026
Same author

Rethinking indications for prophylactic central neck dissection in papillary thyroid microcarcinoma: A real-world retrospective study.

American journal of otolaryngology·2026
Same author

Comparative effectiveness of radical surgery versus concurrent chemoradiotherapy in stages IB3, IIA2, or locally resectable IIICr cervical cancer: a prospective, multicenter, propensity score-matched cohort study.

BMC cancer·2026
Same author

Posterior minimal extrathyroidal extension as an independent risk factor for lateral lymph node metastasis in papillary thyroid carcinoma: a retrospective study based on a nomogram prediction model.

Frontiers in endocrinology·2026
Same author

Autonomic nervous system dysfunction in irritable bowel syndrome: pathophysiology and therapeutic implications.

Frontiers in neuroscience·2026

Related Experiment Video

Updated: May 15, 2026

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

Itopride therapy for functional dyspepsia: a meta-analysis.

Xuan Huang1, Bin Lv, Shuo Zhang

  • 1Department of Gastroenterology, The First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou 310006, Zhejiang Province, China.

World Journal of Gastroenterology
|January 18, 2013
PubMed
Summary

Itopride effectively treats functional dyspepsia (FD) symptoms like fullness and early satiety, with results comparable to other treatments and a low adverse effect rate. This study confirms itopride

Keywords:
Functional dyspepsiaItoprideMeta-analysisProkinetic agentsRandomized controlled trials

More Related Videos

Functional Assessment of Intestinal Motility and Gut Wall Inflammation in Rodents: Analyses in a Standardized Model of Intestinal Manipulation
09:44

Functional Assessment of Intestinal Motility and Gut Wall Inflammation in Rodents: Analyses in a Standardized Model of Intestinal Manipulation

Published on: September 11, 2012

Using An In Vitro Tissue Perfusion System to Detect the Functional Activities of Isolated Intestinal Tubes in Real Time
06:01

Using An In Vitro Tissue Perfusion System to Detect the Functional Activities of Isolated Intestinal Tubes in Real Time

Published on: July 26, 2024

Related Experiment Videos

Last Updated: May 15, 2026

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

Functional Assessment of Intestinal Motility and Gut Wall Inflammation in Rodents: Analyses in a Standardized Model of Intestinal Manipulation
09:44

Functional Assessment of Intestinal Motility and Gut Wall Inflammation in Rodents: Analyses in a Standardized Model of Intestinal Manipulation

Published on: September 11, 2012

Using An In Vitro Tissue Perfusion System to Detect the Functional Activities of Isolated Intestinal Tubes in Real Time
06:01

Using An In Vitro Tissue Perfusion System to Detect the Functional Activities of Isolated Intestinal Tubes in Real Time

Published on: July 26, 2024

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Clinical Trials

Background:

  • Functional dyspepsia (FD) is a common gastrointestinal disorder characterized by persistent upper abdominal symptoms.
  • Current therapeutic options for FD vary, necessitating evaluation of effective treatments like itopride.
  • Comparing itopride with placebo, domperidone, and mosapride provides comprehensive insights into its efficacy.

Purpose of the Study:

  • To systematically evaluate the therapeutic efficacy of itopride compared to placebo, domperidone, and mosapride in managing functional dyspepsia.
  • To assess the impact of itopride on key FD symptoms including global patient assessment, postprandial fullness, and early satiety.
  • To analyze the safety profile and adverse effects associated with itopride treatment in FD patients.

Main Methods:

  • A meta-analysis of randomized controlled trials (RCTs) investigating itopride for functional dyspepsia was conducted.
  • Data extraction and analysis involved calculating relative risk (RR) and weighted mean deviation, employing random or fixed effect models.
  • Publication bias was assessed using visual inspection of funnel plots.

Main Results:

  • Nine RCTs involving 2620 patients demonstrated that itopride significantly improved global patient assessment (RR 1.11), postprandial fullness (RR 1.21), and early satiety (RR 1.24) compared to controls.
  • Itopride use resulted in a significant reduction in the Leeds Dyspepsia Questionnaire score (WMD -1.38).
  • The incidence of adverse effects was comparable between the itopride and control groups, with no evidence of publication bias.

Conclusions:

  • Itopride exhibits significant therapeutic efficacy in improving global patient assessment and specific symptoms of functional dyspepsia, including postprandial fullness and early satiety.
  • Itopride demonstrates a favorable safety profile with a low rate of adverse reactions.
  • Itopride is an effective treatment option for improving overall functional dyspepsia symptom scores.